Research Topics
Species | Martine PiccartSummaryAffiliation: Institut Jules Bordet Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancerM J Piccart
Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo 125, 1000, Brussels, Belgium
Eur J Cancer 38:S52-4. 2002
New developments in hormone receptor-positive diseaseMartine J Piccart-Gebhart
Medicine Department, Jules Bordet Institut, Brussels, Belgium
Oncologist 15:18-28. 2010..This article addresses these important outstanding issues with respect to HR(+) disease...
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Natasa Snoj
Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, Brussels, Belgium
Breast Cancer Res 11:201. 2009....- Targeted therapies in breast cancer: are heart and vessels also being targeted?Carmen Criscitiello
Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, 1000 Brussels, Belgium
Breast Cancer Res 14:209. 2012..In this review, we aim to assess the incidence of cardiac adverse events associated with targeted therapies designed to block HER2 and angiogenic pathways... - Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta
Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
Breast Cancer Res 14:R70. 2012.... - Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho
Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
J Clin Oncol 31:1954-60. 2013..To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial... - Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 30:1879-87. 2012.... - Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesPratyaksha Wirapati
Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
Breast Cancer Res 10:R65. 2008.... - Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerSherene Loi
Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
BMC Med Genomics 2:37. 2009..CONCLUSION: These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype... - Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifenSherene Loi
Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
BMC Genomics 9:239. 2008..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings... - Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancerM J Piccart-Gebhart
Department of Medicine, Jules Bordet Institute, Brussels, Belgium
Ann Oncol 18:xii2-7. 2007..Close collaboration between clinicians and scientists will be essential to achieve this goal... - Bringing molecular prognosis and prediction to the clinicMariantonietta Colozza
S C Oncologia Medica, Azienda Ospedaliera, Perugia, Italy
Clin Breast Cancer 6:61-76. 2005.... - Adjuvant chemotherapy in 2005: standards and beyondM J Piccart
Medical Oncology Clinic, Jules Bordet Institute, Centre des Tumeurs de l Universite Libre de Bruxelles, Rue Heger Bordet, 1, 1000 Brussels, Belgium
Breast 14:439-45. 2005.... - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart
Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
N Engl J Med 353:1659-72. 2005..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy... - Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learnMartine J Piccart-Gebhart
Medicine Department, Jules Bordet Institute, Rue Heger Bordet, 1, Boulevard de Waterloo 125, 1000 Brussels, Belgium
Eur J Cancer 42:1715-9. 2006.... - Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancerM J Piccart
Jules Bordet Institute, Belgian and Luxembourg Cooperative Centers, and Pharmacia Upjohn, Brussels, Belgium
J Clin Oncol 19:3103-10. 2001.... - New developments in hormone receptor-positive diseaseMartine J Piccart-Gebhart
Medicine Department, Jules Bordet Institut, Brussels, Belgium
Oncologist 16:40-50. 2011..This article addresses these important outstanding issues with respect to HR(+) disease... - Proposed treatment guidelines for HER2-positive metastatic breast cancer in EuropeM J Piccart
Institut Jules Bordet, Brussels, Belgium
Ann Oncol 12:S89-94. 2001.... - Current and future potential roles of the platinum drugs in the treatment of ovarian cancerM J Piccart
Jules Bordet Institute, Chemotherapy Unit, Brussels, Belgium
Ann Oncol 12:1195-203. 2001.... - Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancerM Piccart
Chemotherapy Unit, Internal Medicine and Oncology, Jules Bordet Institute, Brussels, Belgium
Ann Oncol 14:1017-25. 2003.... - The role of taxanes in the adjuvant treatment of early stage breast cancerMartine Piccart
Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
Breast Cancer Res Treat 79:S25-34. 2003..Completion of ongoing trials and maturation of the current data will further define the role of taxanes in the adjuvant treatment of early stage breast cancer... - Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancerM J Piccart
EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium
Int J Gynecol Cancer 13:144-8. 2003.... - Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapyM J Piccart
Jules Bordet Institute, Brussels, Belgium
Int J Gynecol Cancer 13:196-203. 2003..89 (0.59-1.33) and 0.82 (0.52-1.29). These results are suggestive of a treatment benefit but do not support a change in clinical practice. Other randomized clinical trials of intraperitoneal CT are reviewed and briefly discussed... - New data on chemotherapy in the adjuvant settingM J Piccart
Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
Breast 12:373-8. 2003..The 3-year results of this trial strongly support concept 1; a longer follow-up and a confirmation study are desirable before recommending changes in routine patient care... - Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerMartine J Piccart-Gebhart
Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
J Clin Oncol 26:1980-6. 2008..This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival... - Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancerMartine Piccart
Institut Jules Bordet, Department of Medicine, Brussels, Belgium
Clin Breast Cancer 8:S100-13. 2008.... - Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysisHatem A Azim
Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
PLoS ONE 8:e62451. 2013..SPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast cancer (BC)... - Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancerFrançoise Rothé
Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
PLoS ONE 6:e20980. 2011..In this study, we investigated miRNA profiling as a complementary tool to improve our understanding of breast cancer (BC) biology and to assess whether miRNA expression could predict clinical outcome of BC patients... - Comparison of prognostic gene expression signatures for breast cancerBenjamin Haibe-Kains
Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
BMC Genomics 9:394. 2008..However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms... - Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trialAndrew Bottomley
European Organisation for Research and Treatment of Cancer, EORTC Data Center, Qualtiy of Life Unit, Brussels, Belgium
Lancet Oncol 6:287-94. 2005..We aimed to compare the effects of such an approach with those of standard chemotherapy on health-related quality of life (HRQOL)... - Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerOtto Metzger-Filho
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
PLoS ONE 8:e66848. 2013..In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its impact on treatment recommendations... - Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysisMichail Ignatiadis
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 30:1996-2004. 2012..To investigate the association between chemotherapy response and gene expression modules describing important biologic processes and druggable oncogenic pathways in breast cancer (BC) subtypes... - Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironmentChristine Desmedt
Breast Cancer Translational Research Laboratory JC Heuson, Institut Jules Bordet, 125 Bld de Waterloo, Brussels 1000, Belgium
Clin Cancer Res 18:1004-14. 2012..Based on earlier research suggesting that during breast cancer progression, striking changes occur in CD10(+) stromal cells, we aimed to better characterize this cell population and its clinical relevance... - Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissuesJérôme Toussaint
Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
BMC Genomics 10:424. 2009.... - What clinicians need to know about antioestrogen resistance in breast cancer therapyAmalia Milano
Medical Oncology and Translational Research Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
Eur J Cancer 42:2692-705. 2006..Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed... - Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts
Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
Nat Clin Pract Oncol 3:540-51. 2006..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment... - [News in the medical treatment of breast cancer]Martine Piccart
Unite de Chimiotherapie, Institut Jules Bordet, 1, Rue Heger Bordet, 1000 Bruxelles, Belgique
Bull Cancer 90:46-52. 2003..For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice... - Gene profiling assay and application: the predictive role in primary therapyDebora Fumagalli
Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium
J Natl Cancer Inst Monogr 2011:124-7. 2011.... - Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISHChristine Desmedt
Department of Medical Oncology, Jules Bordet Institute, Brussels
Diagn Mol Pathol 18:22-9. 2009..27 (HER2:HER2 dimers)]. These data suggest that more quantitative or functional measurements of HER2 status may facilitate the development of more personalized treatment strategies for patients with metastatic breast cancer... - Beyond trastuzumab: new treatment options for HER2-positive breast cancerKamal S Saini
Breast International Group, Brussels, Belgium
Breast 20:S20-7. 2011..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies... - A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpointsDebora Fumagalli
Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
Lancet Oncol 13:e240-8. 2012..We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer... - The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen responseSherene Loi
Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
Crit Rev Oncol Hematol 61:187-94. 2007.... - Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisChristos Sotiriou
Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
J Natl Cancer Inst 98:262-72. 2006..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading... - A fuzzy gene expression-based computational approach improves breast cancer prognosticationBenjamin Haibe-Kains
Functional Genomics and Translational Research Unit, Medical Oncology Department, Jules Bordet Institute, boulevard de Waterloo, Brussels, 1000, Belgium
Genome Biol 11:R18. 2010..In systematic evaluations, GENIUS significantly outperformed current gene signatures and clinical indices in the global population of patients... - Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic mannerFatima Cardoso
Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
Mol Cancer Ther 5:3042-51. 2006.... - Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for ReAndrew Bottomley
Quality of Life Unit, European Organization for Research and Treatment of Cancer Data Center, Insitut Jules Bordet, Brussels, Belgium
J Clin Oncol 22:2576-86. 2004..To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment... - Use of trastuzumab for the treatment of early stage breast cancerSofia Braga
Chemotherapy Unit, Department of Medicine, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
Expert Rev Anticancer Ther 6:1153-64. 2006.... - Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patientsChristine Desmedt
Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
Int J Cancer 119:2539-45. 2006.... - Breast cancer gene expression profiling: clinical trial and practice implicationsSherene Loi
Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
Pharmacogenomics 6:49-58. 2005..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care... - Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancerLissandra Dal Lago
Translational Research Unit, Bordet Institute, Brussels, Belgium
Mol Cancer Ther 5:2572-9. 2006..This project aimed to determine the optimal scoring method for fluorescence in situ hybridization (FISH) assay... - Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic
BrEAST Data Center, Medical Oncology Department, Institut Jules Bordet, Boulevard de Waterloo 121, Brussels, Belgium Medical Oncology Department, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia Electronic address
Breast 23:473-81. 2014..BCL2 expression in the TU but not in the LN was predictive of increased benefit to CMF vs anthracycline-based chemotherapy. .. - Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trialLaura Biganzoli
IDBBC Unit, EORTC IDBBC, Jules Bordet Institute, Boulevard de Waterloo 121, 7th Floor, 1000 Brussels, Belgium
Cancer 97:40-5. 2003..The potential cardiotoxicity of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies... - The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokineticsAhmad Awada
Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
Eur J Cancer 44:84-91. 2008..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone... - Trastuzumab for early breast cancer: current status and future directionsPhuong Dinh
Breast European Adjuvant Study Team, Institut Jules Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
Clin Adv Hematol Oncol 5:707-17. 2007..It also evaluates the current status of trastuzumab as a result of these studies and explores the possible future direction for HER2-positive breast cancers in light of recent advances in translational oncology... - Biology of breast cancer during pregnancy using genomic profilingHatem A Azim
Department of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, BelgiumDepartment of MedicineInstitut Jules Bordet, BrEAST Data Centre, Universite Libre de Bruxelles ULB, boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory BCTL J C HeusonInstitut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Department of Forest Ecology
Endocr Relat Cancer 21:545-54. 2014..No genes were associated with DFS in a multivariate model, which could be due to low statistical power. Diagnosis during pregnancy impacts the breast cancer transcriptome including potential cancer targets. .. - Progress and new standards of care in the management of HER-2 positive breast cancerGaston Demonty
Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
Eur J Cancer 43:497-509. 2007..The results of the recently reported adjuvant trials are commented, as the positive results of these trials changed the standard of care for patients with this particular type of breast cancer... - Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq
Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
Mol Cancer Ther 3:1207-14. 2004..The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel... - DNA methylation profiling reveals a predominant immune component in breast cancersSarah Dedeurwaerder
Laboratory of Cancer Epigenetics, Faculty of Medicine, Universite Libre de Bruxelles, Brussels, Belgium
EMBO Mol Med 3:726-41. 2011..The immune component uncovered here by DNA methylation profiles provides a new perspective for the importance of the microenvironment in breast cancer, holding implications for better management of breast cancer patients... - HER2-positive circulating tumor cells in breast cancerMichail Ignatiadis
Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
PLoS ONE 6:e15624. 2011..Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging... - [Has the time arrived for gene expression use at the bedside?]Véronique D'Hondt
Service de Medecine Interne, Clinique d oncologie médicale, Institut Jules Bordet, 121, boulevard de Waterloo Bruxelles 1000, Belgique
Bull Cancer 95:336-43. 2008..Here we describe the state of the art of gene expression profiling for breast cancer, and we discuss the potential impact on breast cancer patient management considering its limits and promises... - Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancerPhilippe L Bedard
Department of Medical Oncology, Jules Bordet Institute, Rue Heger Bordet 1, Brussels, Belgium
Nat Rev Clin Oncol 7:22-36. 2010..Inclusion criteria for future clinical trials must be revised to account for the molecular heterogeneity of breast cancer and further optimize the role of adjuvant taxane therapy in early-stage disease... - Aiming at the target: improved adjuvant medical therapyPhilippe L Bedard
Department of Medical Oncology, Jules Bordet Institute, Rue Heger Bordet 1, Brussels, Belgium
Breast 18:S25-30. 2009..It is hoped that coupling prospective biomarker discovery with new drug development in earlier stages of disease will yield additional targets that can be used to guide clinical decision-making in the future... - Facts and controversies in the use of trastuzumab in the adjuvant settingPhuong Dinh
Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
Nat Clin Pract Oncol 5:645-54. 2008..This Review outlines the five adjuvant trastuzumab studies and discusses the controversies and challenges that have emerged for both the clinician and healthcare authorities worldwide as a consequence of the results from these trials... - 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTOGeraldine Gebhart
Nuclear Medicine Department, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
J Nucl Med 54:1862-8. 2013..The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients... - Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot studyGilles Freyer
Laboratoire d Oncopharmacologie, Unite de Chimiotherapie, Service de Médecine Interne et Laboratoire d Investigation Clinique et d Oncologie Expérimentale HJ Tagnon, Institut Jules Bordet, 1000, Brussels, Belgium
Clin Cancer Res 8:95-102. 2002..For the other toxicities, which are usually cumulative, the present study has design limitations and further comparative trials are warranted... - New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspectiveAhmad Awada
Chemotherapy Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
Expert Rev Anticancer Ther 4:53-60. 2004..A clinical perspective of these agents as monotherapy or combination therapy will be presented in this paper... - A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignanciesAhmad Awada
Jules Bordet Institute, Brussels, Belgium
Curr Med Res Opin 23:991-1003. 2007..This phase I study assessed the maximum tolerated doses (MTDs), safety, pharmacokinetics, and efficacy of combined tipifarnib and docetaxel treatment in patients with advanced solid malignancies... - New therapies for ovarian cancer: cytotoxics and molecularly targeted agentsPhuong Dinh
Institut Jules Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
Crit Rev Oncol Hematol 67:103-12. 2008..It will also discuss other potential signal transduction targets worthy of further evaluation in future trials... - Better translation from bench to bedside: breakthroughs in the individualized treatment of cancerCarolyn Straehle
Breast International Group, Brussels, Belgium
Crit Care Med 37:S22-9. 2009.... - Emerging targeted agents in metastatic breast cancerDimitrios Zardavas
Institut Jules Bordet, Universite Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
Nat Rev Clin Oncol 10:191-210. 2013..This evolution is reflected in the molecular heterogeneity of the disease and poses severe impediments to the successful clinical development of emerging targeted agents... - Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)Felipe Ades
Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Belgium
J Chemother 25:239-46. 2013..We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site. .. - CD4⁺ follicular helper T cell infiltration predicts breast cancer survivalChunyan Gu-Trantien
Molecular Immunology Unit, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Invest 123:2873-92. 2013..Our identification of CD4⁺ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor... - Current paradigms for the use of HER2-targeted therapy in early-stage breast cancerPhilippe L Bedard
Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
Clin Breast Cancer 8:S157-65. 2008..Future studies with novel anti-HER2 strategies will prospectively evaluate biomarkers in an effort to further improve the outcome of women diagnosed with HER2-positive disease... - Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmélie Deleporte
Medicine Department, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
BMC Cancer 14:385. 2014..There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to have a major impact on patient outcome... - The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsHichame Id Boufker
Laboratoire d Hematologie Experimentale, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
BMC Cancer 10:298. 2010..It has also shown promising results in preclinical studies in various solid tumors. However, its effects on the differentiation of human osteoblasts have never been examined... - Personalized therapy for breast cancer: a dream or a reality?Dimitrios Zardavas
Institut Jules Bordet, boulevard de Waterloo, 125, 1000 Brussels, Belgium
Future Oncol 9:1105-19. 2013..Well-conducted prospective validation studies are needed if breast cancer personalized therapy is to transform from a dream into a reality. .. - The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control studyHatem A Azim
Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
Acta Oncol 51:653-61. 2012..Hence, we designed a case-control study to examine tumor features and outcome in a series of BCP patients diagnosed and treated in a single institution... - [Kidney cancer: from biology to clinical medicine]Yassine Lalami
Institut Jules Bordet, Service de Medecine Interne, Clinique d oncologie médicale, Bruxelles, Belgique
Rev Med Suisse 2:600-4, 606-8. 2006 - Brain metastases in HER2-positive breast cancer: the evolving role of lapatinibGianluca Tomasello
Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
Crit Rev Oncol Hematol 75:110-21. 2010..This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases... - Stemming resistance to HER-2 targeted therapyPhilippe L Bedard
Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
J Mammary Gland Biol Neoplasia 14:55-66. 2009..Future clinical trials should involve the integration of technologies to assess the impact of novel HER-2 targeted therapies on HER-2 positive CSCs... - Beyond trastuzumab and lapatinibDimitrios Zardavas
From the Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, United Kingdom and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
Am Soc Clin Oncol Educ Book 2013:2-11. 2013..This paper presents the clinical data of the HER2-targeted agents under development, as well as an overview of the biologic rationale for the development of agents aimed at circumventing anti-HER2 resistance... - The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trialChristine Desmedt
Institut Jules Bordet, , Brussels, Belgium
BMC Med Genomics 2:40. 2009..Validation of these results, in a larger series from BIG 1-98, is planned using the simplified GGI represented by a smaller set of genes and tested by qRT-PCR on paraffin-embedded tissues... - Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancerPhilippe L Bedard
Jules Bordet Institute, Department of Medical Oncology, Belgium
Curr Opin Oncol 21:491-8. 2009..This review will discuss the use of predictive biomarkers to tailor postmenopausal endocrine therapy... - New tools for assessing breast cancer recurrencePhuong Dinh
Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Cancer Treat Res 141:99-118. 2008 - Clinical application of the 70-gene profile: the MINDACT trialFatima Cardoso
Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium
J Clin Oncol 26:729-35. 2008..This article reviews the several steps in the development of the profile from its discovery to its clinical validation... - Mathematics and oncology: a match for life?Martine J Piccart-Gebhart
J Clin Oncol 21:1425-8. 2003 - Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski
Hasselt University, Center for Statistics, Agoralaan, Bldg D, 3590 Diepenbeek, Belgium
J Clin Oncol 26:1987-92. 2008.... - New stars in the sky of treatment for early breast cancerMartine J Piccart-Gebhart
N Engl J Med 350:1140-2. 2004 - Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapyMartine J Piccart-Gebhart
J Clin Oncol 23:1611-3. 2005 - The evolving role of aromatase inhibitors in adjuvant breast cancer therapyI Craig Henderson
Carol Franc Buck Breast Care Center, University of California San Francisco Comprehensive Cancer Center, 94143, USA
Clin Breast Cancer 6:206-15. 2005..In addition, case-based discussions are included to provide direction on how to integrate recent endocrine adjuvant clinical trial findings into everyday practice... - Anthracyclines and the tailoring of treatment for early breast cancerMartine J Piccart-Gebhart
N Engl J Med 354:2177-9. 2006 - 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith
Royal Marsden Hospital, London, UK
Lancet 369:29-36. 2007..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study... - Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialThomas M Suter
Swiss Cardiovascular Center, University Hospital Bern, Inselspital, Bern, Switzerland
J Clin Oncol 25:3859-65. 2007..The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or without radiotherapy... - Individualization of therapy using Mammaprint: from development to the MINDACT TrialStella Mook
Netherlands Cancer Institute, Amsterdam, The Netherlands
Cancer Genomics Proteomics 4:147-55. 2007....